A 12-Week, Open-Label Extension Study For the Treatment of Major Depressive Disorder With Mixed Features.
Phase of Trial: Phase III
Latest Information Update: 02 May 2018
At a glance
- Drugs Lurasidone (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions; Registrational
- Acronyms RESOLVE-3
- 02 May 2018 According to a Sunovion Pharmaceuticals media release, data from this trial will be presented at the American Psychiatric Association (APA) Annual Meeting (2018).
- 01 Oct 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Sep 2013 Planned End Date changed from 1 Jul 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.